How Did Scientists Learn to Block GM-CSF?
🌏 Available in: English | 한국어
How Did Scientists Learn to Block GM-CSF? The Story Behind Anti-GM-CSF Medicines
From Growth Factor to Drug Target
When Australian scientist Professor Don Metcalf and his colleagues first discovered granulocyte-macrophage colony-stimulating factor (GM-CSF), together with other colony-stimulating factors such as G-CSF, they initially believed they had identified another growth factor involved in white blood cell production.
For years, that assumption seemed correct.
GM-CSF was viewed primarily as a molecule that stimulated bone marrow to generate granulocytes and macrophages, helping cancer patients recover after chemotherapy or bone marrow transplantation.
World-renowned tenor José Carreras was able to overcome leukemia after participating in a pioneering clinical trial of GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor), highlighting the life-saving potential of this groundbreaking discovery.
But science rarely follows a straight line.
As researchers continued studying GM-CSF, they noticed something unexpected.
In many inflammatory diseases, patients were not simply producing more immune cells.
Those immune cells were behaving differently.
They were surviving longer, producing more inflammatory cytokines, recruiting additional immune cells, and sustaining chronic inflammation.
GM-CSF was not merely making immune cells.
It was instructing them how aggressively to fight.
That realization changed everything.
The Master Switch of Inflammation
Unlike cytokines that activate a single pathway, GM-CSF influences multiple immune cell types simultaneously.
Macrophages become highly inflammatory.
Monocytes are recruited into damaged tissues.
Dendritic cells present antigens more efficiently.
Neutrophils survive longer.
Rather than acting as one soldier on the battlefield, GM-CSF behaves more like a battlefield commander.
Once scientists understood this, an obvious question emerged.
What if we simply switched GM-CSF off?
Rheumatoid Arthritis Led the Way
The first disease to seriously test this idea was rheumatoid arthritis (RA).
Patients with RA often have high concentrations of GM-CSF inside inflamed joints.
Researchers found that GM-CSF continuously activates macrophages, causing them to release cytokines such as TNF, IL-1, and IL-6.
These inflammatory molecules gradually destroy cartilage and bone.
If GM-CSF sits upstream of these cytokines, blocking it might interrupt the entire inflammatory cascade.
Instead of treating the consequences, doctors could intervene much earlier.
Building Anti-GM-CSF Medicines
This idea led to the development of monoclonal antibodies designed either to neutralize GM-CSF itself or block its receptor.
Several drugs entered clinical trials, including:
- Namilumab – targeting GM-CSF
- Otilimab – targeting GM-CSF
- Lenzilumab – targeting GM-CSF
- Mavrilimumab – targeting the GM-CSF receptor
Although not all programs achieved regulatory approval, these studies demonstrated that blocking GM-CSF could reduce inflammation in several immune-mediated diseases and helped establish GM-CSF as a legitimate therapeutic target.
Then Came COVID-19
During the COVID-19 pandemic, GM-CSF returned to the spotlight.
Doctors observed that some critically ill patients died not because the virus continued replicating, but because their immune systems became dangerously overactivated.
This overwhelming inflammatory response became known as the cytokine storm.
GM-CSF was identified as one of the cytokines helping drive this process.
Several anti-GM-CSF antibodies rapidly entered clinical trials to determine whether dampening this pathway could reduce severe lung inflammation.
Although the results varied, the pandemic highlighted how quickly decades of basic immunology research could be translated into clinical testing during a global emergency.
A Connection Back to WEHI
Interestingly, WEHI researchers had already been exploring this pathway in another disease.
Their work suggested that abnormal GM-CSF production was not unique to rheumatoid arthritis or COVID-19.
It could also help explain why inflammation continues after Group A Streptococcus infection has disappeared.
The study further showed that Hydroxychloroquine, a drug already widely used to treat rheumatoid arthritis, could suppress this inflammatory pathway in laboratory experiments, highlighting its potential for repurposing as a therapy for acute rheumatic fever (ARF).
From Discovery to Therapy
When Don Metcalf discovered GM-CSF, few imagined that one day scientists would try to block the very molecule he had helped identify.
Yet this apparent contradiction reflects how biomedical science evolves.
A molecule that promotes healing in one setting may drive disease in another.
Understanding when to enhance a biological pathway—and when to suppress it—is one of the defining challenges of modern medicine.
GM-CSF has become far more than a blood cell growth factor.
It has become one of the central switches controlling inflammation itself.
Conclusion Remarks
The story of GM-CSF reminds us that scientific discoveries rarely have a single destination.
One discovery may first become a laboratory tool, then a medicine, and finally a therapeutic target itself.
That is the remarkable journey of GM-CSF—from helping the immune system grow to teaching scientists how to calm it.
Related Articles
Donald Metcalf: The Scientist Who Discovered G-CSF
How Australian Scientists Discovered a New Immune Pathway in Rheumatic Heart Disease?